South Korean biotech company SK Biopharmaceuticals Co Ltd announced on Wednesday that it has signed a licence agreement with the Wisconsin Alumni Research Foundation (WARF).

Under this agreement SK Biopharmaceuticals will acquire the exclusive global rights for research and development (R&D), manufacturing, and commercialisation of WARF's 'WT-7695', a preclinical-stage radiopharmaceutical therapy candidate developed in partnership with the University of Wisconsin-Madison.

This agreement represents SK Biopharmaceuticals' second in-licensed asset in the radiopharmaceutical therapy field, following its first asset 'SKL35501' (formerly FL-091) in 2024.

WT-7695 is a small-molecule radiopharmaceutical candidate in preclinical stage designed to target carbonic anhydrase IX (CA9), a transmembrane protein that plays a critical role in cancer cell growth and metastasis under hypoxic conditions.

SK Biopharmaceuticals aims to build a comprehensive radiopharmaceutical value chain, encompassing drug discovery, radioisotope sourcing, preclinical and clinical development..